Actively Recruiting
A Brief Values-Based Therapy to Support Veterans Starting Buprenorphine for Opioid Use Disorder Improving Interpersonal Functioning, Community Reintegration, and Quality of Life in Early Medication Treatment
Led by VA Office of Research and Development · Updated on 2026-06-23
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a brief, values-based behavioral intervention to support Veterans with opioid use disorder OUD who are in early buprenorphine treatment. The goal is to improve interpersonal functioning, community reintegration, and quality of life during early medication treatment. The project follows the NIH Stage Model for Behavioral Intervention Development and includes phases for treatment development, pilot testing, and a pilot randomized controlled trial. The intervention consists of four weekly 50-minute sessions focused on values clarification, understanding the connection between values and addiction treatment engagement, addressing barriers and goal setting, and planning recovery. Phase 1 develops and refines the manual using interviews with Veterans and providers. Phase 2 tests the intervention in an open trial with 10 Veterans to refine the treatment and study procedures. Phase 3 involves a pilot trial with 40 Veterans receiving the finalized intervention, assessing feasibility and preliminary effects. Participants will engage in scheduled assessments at baseline, post-treatment, and follow-ups at 3 and 6 months. Assessments include measures of interpersonal functioning, social support, quality of life, substance use, and treatment adherence. Study therapists adherence and competence will be monitored. Data will be securely managed, and participant feedback will guide further refinements. The study period spans multiple years, supporting treatment development and evaluation.
CONDITIONS
Brief Title
A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meets current Diagnostic and Statistical Manual - 5th Edition criteria for moderate to severe opioid use disorder
- Within 12 weeks of starting buprenorphine, methadone, or naltrexone treatment after at least 2 months without treatment
- Able to provide written informed consent
You will not qualify if you...
- Active psychosis or mania
- Suicidality requiring inpatient hospitalization
- Active substance use requiring detoxification
- Cognitive impairment interfering with study participation
Research Team
V
Victoria Ameral, PhD
A
Anne Marie Hernon
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here